An experimental approach combining oral Wnt-blocking therapy with lenvatinib showed durable tumor shrinkage in advanced endometrial cancer after immunotherapy and chemotherapy failure. The results were reported from the dose-expansion phase in EClinicalMedicine, highlighting a potential mechanism shift once checkpoint strategies stop working. Separately, researchers identified a molecular driver that helps breast cancer evade PD-1 blockade. The work, published in the Journal of Translational Medicine, points to a stress-linked pathway that may explain resistance patterns and suggests a new target space for immunotherapy reframing. Together, the studies underline a recurring clinical theme: when immunotherapy response falters, teams are pivoting toward pathway inhibition and uncovering host-tumor switches that maintain immune evasion.